AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00866216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals
Study NCT00866216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.
Study NCT01841840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Frequency Passive Vibration
Description: 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
Study NCT01841840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Frequency Pasive Vibration
Description: 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
Study NCT04163666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
Study NCT04163666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapeutic exercise
Description: The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
Study NCT00825474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: operation;TACE plus PEI
Description: Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
Study NCT04937075 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02651558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: OBPM 2015-MD-0022 - CHEST
Description: At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded.
Study NCT02651558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: OBPM 2015-MD-0022 - CHEST & FINGER
Description: At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded.
Study NCT02651558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: OBPM 2015-MD-0022 - FINGER
Description: At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded.
Study NCT00917254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00917254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00917254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: injection
Study NCT04488653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligopin®
Description: French Maritime Pine Bark Extract - 100mg/day
Study NCT04488653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT02359435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy
Description: pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
Study NCT02359435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard triple therapy
Description: pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
Study NCT00707863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: 10 mg of Escitalopram by mouth once a day for 8 weeks
Study NCT02321540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily.
Study NCT02797483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Fat Blue
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
Study NCT02797483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Fat Green
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
Study NCT02797483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Fat Red
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
Study NCT00051311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Recipients will receive donor stem cells 3 days after conditioning therapy is completed.
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study NCT03898843 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rectal swab sampling
Description: All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
Study NCT00555685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 7,5% (Hypertonic Saline Solution)
Description: Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
Study NCT00555685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study NCT02661451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV
Study NCT02661451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Heart Failure Therapy
Study NCT02661451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optimal Heart Failure Therapy
Study NCT02561416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
Study NCT02561416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAU
Description: In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
Study NCT03588767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 + anabolic substance
Description: Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
Study NCT03588767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Vitamin D3 + anabolic substance
Description: Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
Study NCT03123939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients > 50 kg)
Study NCT02847936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vicryl plus suture
Description: episiotomy with triclosan-coated sutures
Study NCT02847936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vicryl suture
Description: episiotomy with non antibacterial coated suture
Study NCT03645837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression clamp release
Description: Standard compression clamp is used and will be released at different times according to randomization
Study NCT00084864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00084864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: No intervention before surgery
Study NCT04628208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spartan COVID-19 v2 System
Description: A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
Study NCT03132311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever vaccination (17 DD Biomanguinhos)
Description: One intramuscular injection
Study NCT03132311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccination (17 DD Biomanguinhos)
Description: One intramuscular injection
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study NCT02440555 — intervention group
Intervention type: OTHER
Intervention: fulfill the self-administered questionnaire
Description: Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
Study NCT00051311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
Study NCT00051311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Apheresis
Description: Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
Study NCT02286661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Casting (long arm)
Description: Casting using plaster of paris after closed reduction of distal radius fracture
Study NCT02286661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Casting (short arm)
Study NCT02295475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02295475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT02919020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Description: Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
Study NCT02919020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: resistance exercise to strengthen lower limbs
Study NCT02944045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day
Study NCT02944045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline serum
Study NCT01050218 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Study NCT01852370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 negative allogeneic hematopoietic stem cells
Description: Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
Study NCT04602689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Description: Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
Study NCT01259687 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive cardiac output monitoring
Description: During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
Study NCT06161883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soffritto
Description: The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
Study NCT02320253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Person Group (IP)
Description: The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
Study NCT02320253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Conference Call Group (TCC)
Description: The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
Study NCT02320253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy (MNT)
Description: Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
Study NCT03022266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive and Mobile Phone App
Description: Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
Study NCT02485353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vosaroxin and Cytarabine
Study NCT01822158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal Delivery Debrief Checklist
Description: Participating team members will utilize Vaginal Delivery Debrief checklist
Study NCT00451698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyanotic erythropoietin
Description: Single dose IV push
Study NCT00451698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acyanotic placebo
Description: Single dose IV push
Study NCT03937687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine+TeaCrine+Dynamine
Description: combination of caffeine, TeaCrine, and Dynamine
Study NCT03937687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03937687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine
Study NCT00503568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad100-gp96Ig-HLA A1
Description: Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
Study NCT00699933 — intervention group
Intervention type: OTHER
Intervention: CT-guided percutaneous drainage technique
Description: Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
Study NCT03645837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression clamp release
Description: Standard compression clamp is used and will be released at different times according to randomization
Study NCT03872583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Understanding MRI in MS (website)
Description: Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
Study NCT04222387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-B scan
Description: OCT-B scan (Optical coherence tomography)
Study NCT00810303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetrol (ezetimibe) multiple dose
Description: administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
Study NCT00810303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose
Description: administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)